-
Progenics Shares Could Double, According To Cantor
Wednesday, July 12, 2017 - 2:58pm | 415Read More...Cantor Fitzgerald analyst Mara Goldstein initiated coverage on Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) with an Overweight rating and $15 price target. The stock jumped 2.4 percent Wednesday to $6.86; the price target represents a 114 percent upside. Goldstein believes the company will gain...
-
Exclusive: Progenics CEO Talks Regulatory Climate, Positive Trials For Ultra-Orphan Azedra
Monday, April 3, 2017 - 1:58pm | 625Read More...From healthcare to finance to natural resources, everyone is reeling from federal administration shakeups and their various market implications. But Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) CEO Mark Baker is unconcerned by leadership and regulatory changes at the U.S. Food and Drug...
